Join to View Full Profile
800 Ridgeview DriveHorsham, PA 19044
Dr. Lin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Thomas Lin is a hematologist-oncologist based in Horsham, PA, with a subspecialty in hematologic malignancies. He graduated from the MD/PhD program at Yale University in 1995 and completed his Internal Medicine residency at Brigham and Women's Hospital in 1997 and a hematology-oncology fellowship at Dana-Farber Cancer Institute, BWH and MGH in 2001. He was an Associate Professor at Ohio State from 2001 to 2009. He was the R&D lead for ofatumumab (Arzerra) at GSK from 2009 to 2014, and he has been at Johnson & Johnson since 2014, where he currently the Head of Multiple Myeloma in US medical affairs. He has authored or co-authored more than 280 publications and abstracts in CLL, lymphoma, stem cell transplant and multiple myeloma, and he has first and senior author publications in journals such as JCO, Blood and Lancet Hematology.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1997 - 2000- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1995 - 1997
Yale School of MedicineClass of 1995
Certifications & Licensure
PA State Medical License 2011 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Publications & Presentations
PubMed
- 40 citationsDaratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.Ashraf Badros, Laahn Foster, Larry D Anderson Jr, Chakra P Chaulagain, Erin Pettijohn
Blood. 2025-01-16 - 1 citationsA plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2025-01-01 - 25 citationsDaratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves
Blood Cancer Journal. 2024-07-08
Abstracts/Posters
- Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo...Thomas S. Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo...Thomas S. Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
